TOT BIOPHARM International Company (1875) Stock Overview

TOT BIOPHARM International Company Limited, an investment holding company, engages in the research, development, manufacturing, and marketing of anti-tumor drugs in China. The company develops TAB008 for the treatment of non-squamous non-small-cell lung cancer, metastatic colorectal cancer, glioblastoma multiforme, ovarian cancer, cervical cancer, fallopian tube cancer, or primary peritoneal cancer, and hepatocellular carcinoma. It also offers TOZ309 for the treatment of glioblastoma multiforme or anaplastic astrocytoma. In addition, the company develops TAA013 for HER2+ breast cancer; TAE020 which is under preclinical trial for acute myeloid leukemia; and TAB014 for wet age-related macular degeneration. Further it develops TAC020 for the treatment various solid tumors. TOT BIOPHARM International Company Limited was incorporated in 2009 and is headquartered in Suzhou, China.